General introduction
1.8 The aims of the research for this thesis were:
1. To investigate the biophysics and biological relevance of nanostructure formation by model neuropeptides
1.1. To determine the influence of pH, ionic strength and concentration on peptide nanostructure formation.
1.2. To determine the influence of aggregation helpers on peptide nanostructure formation. 2. To investigate the interactions of functional amyloid nanostructures and disease-associated
amyloid fibrils with different brain cells.
3. To design biomaterials from model neuropeptides using their self-assembling properties.
1.9 References
1. Chiti, F., et al., Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proceedings of the National Academy of Sciences, 1999. 96(7): p. 3590- 3594.
2. Dobson, C.M., Protein misfolding, evolution and disease. Trends in biochemical sciences, 1999. 24(9): p. 329-332.
3. Knowles, T.P., M. Vendruscolo, and C.M. Dobson, The amyloid state and its association with protein misfolding diseases. Nature reviews Molecular cell biology, 2014. 15(6): p. 384.
4. Knowles, T.P., et al., Role of intermolecular forces in defining material properties of protein nanofibrils. Science, 2007. 318(5858): p. 1900-1903.
27 5. Chernoff, Y.O., Amyloidogenic domains, prions and structural inheritance: rudiments of early life or recent acquisition? Current opinion in chemical biology, 2004. 8(6): p. 665-671.
6. Kelly, J.W., The alternative conformations of amyloidogenic proteins and their multi- step assembly pathways. Current opinion in structural biology, 1998. 8(1): p. 101-106. 7. van der Linden, E. and P. Venema, Self-assembly and aggregation of proteins.
Current Opinion in Colloid & Interface Science, 2007. 12(4-5): p. 158-165.
8. Yan, X., P. Zhu, and J. Li, Self-assembly and application of diphenylalanine-based nanostructures. Chemical Society Reviews, 2010. 39(6): p. 1877-1890.
9. Lara, C., S. Handschin, and R. Mezzenga, Towards lysozyme nanotube and 3D hybrid self-assembly. Nanoscale, 2013. 5(16): p. 7197-7201.
10. Dehsorkhi, A., V. Castelletto, and I.W. Hamley, Self‐assembling amphiphilic peptides. Journal of Peptide Science, 2014. 20(7): p. 453-467.
11. Sunde, M., et al., Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of molecular biology, 1997. 273(3): p. 729-739.
12. Serpell, L.C., Alzheimer’s amyloid fibrils: structure and assembly. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2000. 1502(1): p. 16-30.
13. Makin, O.S. and L.C. Serpell, Structures for amyloid fibrils. Febs Journal, 2005. 272(23): p. 5950-5961.
14. Riek, R. and D.S. Eisenberg, The activities of amyloids from a structural perspective. Nature, 2016. 539(7628): p. 227.
15. Eanes, E. and G. Glenner, X-ray diffraction studies on amyloid filaments. Journal of Histochemistry & Cytochemistry, 1968. 16(11): p. 673-677.
16. F, P.H.S., Congo red as a stain for
fluorescence microscopy of amyloid. J Histochem Cytochem, 1965. 13: p. 693–694.
17. Levine, H., Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution. Protein Science, 1993. 2(3): p. 404-410.
18. Landreh, M., et al., The formation, function and regulation of amyloids: insights from structural biology. Journal of internal medicine, 2016. 280(2): p. 164-176.
19. Luca, S., et al., Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry, 2007. 46(47): p. 13505- 13522.
20. Gath, J., et al., Unlike twins: an NMR comparison of two α-synuclein polymorphs featuring different toxicity. PLoS One, 2014. 9(3): p. e90659.
21. Fitzpatrick, A.W., et al., Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proceedings of the National Academy of Sciences, 2013: p. 201219476.
22. Colletier, J.-P., et al., Molecular basis for amyloid-β polymorphism. Proceedings of the National Academy of Sciences, 2011. 108(41): p. 16938-16943.
23. Dobson, C.M. Principles of protein folding, misfolding and aggregation. in Seminars in cell & developmental biology. 2004. Elsevier.
24. Hirschfield, G.M. Amyloidosis: a clinico-pathophysiological synopsis. in Seminars in cell & developmental biology. 2004. Elsevier.
25. Mattson, M.P., Pathways towards and away from Alzheimer's disease. Nature, 2004. 430(7000): p. 631-639.
26. Sadqi, M., et al., α-Helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry, 2002. 41(22): p. 7150-7155.
28 27. Harrison, R., et al., Amyloid peptides and proteins in review, in Reviews of
physiology, biochemistry and pharmacology. 2007, Springer. p. 1-77.
28. Barnhart MM, C.M., Curli biogenesis and function. Annu Rev Microbiol, 2006. 60: p. 131-147.
29. Iconomidou, V.A., G. Vriend, and S.J. Hamodrakas, Amyloids protect the silkmoth oocyte and embryo. FEBS letters, 2000. 479(3): p. 141-145.
30. True, H.L. and S.L. Lindquist, A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature, 2000. 407(6803): p. 477-483.
31. Talbot, N.J., Aerial morphogenesis: enter the chaplins. Current Biology, 2003. 13(18): p. R696-R698.
32. John M. Kenney, et al., Amyloidogenic nature of spider silk. Eur. J. Biochem, 2002. 269(16): p. 4159–4163.
33. Fowler, D.M., et al., Functional amyloid formation within mammalian tissue. PLoS Biol, 2005. 4(1): p. e6.
34. Westermark, P., et al., Prolactin-derived amyloid in the aging pituitary gland. The American journal of pathology, 1997. 150(1): p. 67.
35. Jacob, R.S., et al., Amyloid formation of growth hormone in presence of zinc: Relevance to its storage in secretory granules. Scientific Reports, 2016. 6.
36. Van Grondelle, W., et al., Spontaneous fibrillation of the native neuropeptide hormone Somatostatin-14. Journal of structural biology, 2007. 160(2): p. 211-223. 37. Singh, P.K. and S.K. Maji, Amyloid-like fibril formation by tachykinin neuropeptides
and its relevance to amyloid β-protein aggregation and toxicity. Cell biochemistry and biophysics, 2012. 64(1): p. 29-44.
38. Maji, S.K., et al., Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science, 2009. 325(5938): p. 328-332.
39. Dannies, P.S., Protein Hormone Storage in Secretory Granules: Mechanisms for Concentration and Sorting 1. Endocrine reviews, 1999. 20(1): p. 3-21.
40. Keeler, C., M.E. Hodsdon, and P.S. Dannies, Is there structural specificity in the reversible protein aggregates that are stored in secretory granules? Journal of Molecular Neuroscience, 2004. 22(1-2): p. 43-49.
41. Snow, A.D., et al., Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta neuropathologica, 1989. 77(4): p. 337-342.
42. Cohlberg, J.A., et al., Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry, 2002. 41(5): p. 1502-1511. 43. Roher, A.E., et al., Morphological and biochemical analyses of amyloid plaque core
proteins purified from Alzheimer disease brain tissue. Journal of neurochemistry, 1993. 61(5): p. 1916-1926.
44. Mihov, D. and M. Spiess, Glycosaminoglycans: Sorting determinants in intracellular protein traffic. Int J Biochem Cell Biol, 2015. 68: p. 87-91.
45. Jha, N.N., et al., Characterization of amyloid formation by glucagon-like peptides: role of basic residues in heparin-mediated aggregation. Biochemistry, 2013. 52(49): p. 8800-8810.
46. van Grondelle, W., et al., Lamination and spherulite-like compaction of a hormone’s native amyloid-like nanofibrils: spectroscopic insights into key interactions. Faraday discussions, 2013. 166: p. 163-180.
47. Ranganathan, S., et al., Molecular interpretation of ACTH-β-endorphin coaggregation: relevance to secretory granule biogenesis. PLoS One, 2012. 7(3): p. e31924.
29 48. Nettleton, E.J., et al., Characterization of the oligomeric states of insulin in self-
assembly and amyloid fibril formation by mass spectrometry. Biophysical Journal, 2000. 79(2): p. 1053-1065.
49. Bouchard, M., et al., Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Science, 2000. 9(10): p. 1960-1967.
50. Marcon, G., et al., Amyloid formation from HypF-N under conditions in which the protein is initially in its native state. Journal of molecular biology, 2005. 347(2): p. 323-335.
51. Chapman, M.R., et al., Role of Escherichia coli curli operons in directing amyloid fiber formation. Science, 2002. 295(5556): p. 851-855.
52. Destoumieux‐Garzón, D., et al., Microcin E492 antibacterial activity: evidence for a TonB‐dependent inner membrane permeabilization on Escherichia coli. Molecular microbiology, 2003. 49(4): p. 1031-1041.
53. Claessen, D., et al., A novel class of secreted hydrophobic proteins is involved in aerial hyphae formation in Streptomyces coelicolor by forming amyloid-like fibrils. Genes & development, 2003. 17(14): p. 1714-1726.
54. Oh, J., et al., Amyloidogenesis of type III-dependent harpins from plant pathogenic bacteria. Journal of Biological Chemistry, 2007. 282(18): p. 13601-13609.
55. Baxa, U., et al., Filaments of the Ure2p prion protein have a cross-β core structure. Journal of structural biology, 2005. 150(2): p. 170-179.
56. Wösten, H.A. and M.L. de Vocht, Hydrophobins, the fungal coat unravelled. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, 2000. 1469(2): p. 79-86.
57. Coustou, V., et al., The protein product of the het-s heterokaryon incompatibility gene of the fungus Podospora anserina behaves as a prion analog. Proceedings of the National Academy of Sciences, 1997. 94(18): p. 9773-9778.
58. Si, K., S. Lindquist, and E.R. Kandel, A neuronal isoform of the aplysia CPEB has prion-like properties. Cell, 2003. 115(7): p. 879-891.
59. Alberti, S., et al., A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell, 2009. 137(1): p. 146-158.
60. Dharmadana, D., et al., Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design. 2017. 7(4): p. 20160160.
61. Arosio, P., T.P. Knowles, and S. Linse, On the lag phase in amyloid fibril formation. Physical Chemistry Chemical Physics, 2015. 17(12): p. 7606-7618.
62. Cohen, S.I., et al., Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proceedings of the National Academy of Sciences, 2013. 110(24): p. 9758-9763.
63. Meisl, G., et al., Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proceedings of the National Academy of Sciences, 2014: p. 201401564.
64. Buell, A.K., et al., Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proceedings of the National Academy of Sciences, 2014. 111(21): p. 7671-7676.
65. Baldwin, A.J., et al., Metastability of native proteins and the phenomenon of amyloid formation. Journal of the American Chemical Society, 2011. 133(36): p. 14160- 14163.
66. Hartl, F.U. and M. Hayer-Hartl, Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol, 2009. 16(6): p. 574-581.
30 67. Serio, T.R., et al., Nucleated conformational conversion and the replication of
conformational information by a prion determinant. Science, 2000. 289(5483): p. 1317-1321.
68. Caughey, B. and P.T. Lansbury Jr, Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders*. Annual review of neuroscience, 2003. 26(1): p. 267-298.
69. Gibson, T.J. and R.M. Murphy, Inhibition of insulin fibrillogenesis with targeted peptides. Protein science, 2006. 15(5): p. 1133-1141.
70. Wei, G., et al., Self-assembling peptide and protein amyloids: from structure to tailored function in nanotechnology. Chemical Society Reviews, 2017. 46(15): p. 4661-4708.
71. Hardy, J.A. and G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992. 256(5054): p. 184.
72. Pieri, L., et al., Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophysical journal, 2012. 102(12): p. 2894-2905.
73. Silveira, J.R., et al., The most infectious prion protein particles. Nature, 2005. 437(7056): p. 257.
74. Walsh, D.M. and D.J. Selkoe, Aβ oligomers–a decade of discovery. Journal of neurochemistry, 2007. 101(5): p. 1172-1184.
75. Abedini, A., et al., Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics. Elife, 2016. 5: p. e12977.
76. Sakono, M., et al., Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. The FEBS journal, 2008. 275(23): p. 5982-5993. 77. Hamley, I.W., The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s
and fibrillization. Chemical reviews, 2012. 112(10): p. 5147-5192.
78. Sunde, M. and C.C. Blake, From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Quarterly reviews of biophysics, 1998. 31(1): p. 1-39.
79. Sandberg, A., et al., Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering. Proceedings of the National Academy of Sciences, 2010.
107(35): p. 15595-15600.
80. Mulaj, M., J. Foley, and M. Muschol, Amyloid oligomers and protofibrils, but not filaments, self-replicate from native lysozyme. Journal of the American Chemical Society, 2014. 136(25): p. 8947-8956.
81. Liu, C., et al., Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic β-sheet mimics. Journal of the American Chemical Society, 2011. 133(17): p. 6736-6744.
82. Renner, M., et al., Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron, 2010. 66(5): p. 739-754.
83. Guo, C., et al., Triphenylalanine peptides self-assemble into nanospheres and nanorods that are different from the nanovesicles and nanotubes formed by diphenylalanine peptides. Nanoscale, 2014. 6(5): p. 2800-2811.
84. Matsubara, T., et al., Density of GM1 in nanoclusters is a critical factor in the formation of a spherical assembly of amyloid β-protein on synaptic plasma membranes. Langmuir, 2013. 29(7): p. 2258-2264.
85. Kagan, B.L., et al., The channel hypothesis of Alzheimer’s disease: current status. Peptides, 2002. 23(7): p. 1311-1315.
86. Namba, K. and G. Stubbs, Structure of tobacco mosaic virus at 3.6 A resolution: implications for assembly. Science, 1986. 231(4744): p. 1401-1406.
31 87. Inclán, Y.F. and E. Nogales, Structural models for the self-assembly and microtubule interactions of gamma-, delta-and epsilon-tubulin. Journal of cell science, 2001.
114(2): p. 413-422.
88. Valéry, C., et al., Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proceedings of the National Academy of Sciences, 2003. 100(18): p. 10258-10262.
89. Pouget, E., et al., Hierarchical architectures by synergy between dynamical template self-assembly and biomineralization. Nature materials, 2007. 6(6): p. 434.
90. Adamcik, J., et al., Direct Observation of Time‐Resolved Polymorphic States in the Self‐Assembly of End‐Capped Heptapeptides. Angewandte Chemie, 2011. 123(24): p. 5609-5612.
91. Valéry, C., et al., Atomic view of the histidine environment stabilizing higher-pH conformations of pH-dependent proteins. Nature communications, 2015. 6: p. 7771. 92. Zhao, Y., et al., Solvent controlled structural transition of KI4K self-assemblies: from
nanotubes to nanofibrils. Langmuir, 2015. 31(47): p. 12975-12983.
93. Mushnoori, S., et al., Designing phenylalanine-based hybrid biological materials: controlling morphology via molecular composition. Organic & biomolecular chemistry, 2018. 16(14): p. 2499-2507.
94. Tarabout, C., et al., Control of peptide nanotube diameter by chemical modifications of an aromatic residue involved in a single close contact. Proceedings of the National Academy of Sciences, 2011. 108(19): p. 7679-7684.
95. Lara, C., et al., ILQINS Hexapeptide, identified in lysozyme left-handed helical ribbons and nanotubes, forms right-handed helical ribbons and crystals. Journal of the American Chemical Society, 2014. 136(12): p. 4732-4739.
96. Reynolds, N.P., et al., Competition between crystal and fibril formation in molecular mutations of amyloidogenic peptides. Nature Communications, 2017. 8(1): p. 1338. 97. Knowles, T.P., et al., Nanostructured films from hierarchical self-assembly of
amyloidogenic proteins. Nature nanotechnology, 2010. 5(3): p. 204.
98. Zhang, S., et al., Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proceedings of the National Academy of Sciences, 1993. 90(8): p. 3334-3338.
99. Dai, B., et al., Tunable assembly of amyloid-forming peptides into nanosheets as a retrovirus carrier. Proceedings of the National Academy of Sciences, 2015. 112(10): p. 2996-3001.
100. Victor, X.V., et al., Investigating the elusive mechanism of glycosaminoglycan biosynthesis. J Biol Chem, 2009. 284(38): p. 25842-53.
101. Nandini, C.D., N. Itoh, and K. Sugahara, Novel 70-kDa chondroitin sulfate/dermatan sulfate hybrid chains with a unique heterogenous sulfation pattern from shark skin, which exhibit neuritogenic activity and binding activities for growth factors and neurotrophic factors. Journal of Biological Chemistry, 2005. 280(6): p. 4058-4069. 102. SCOTT, J.E., The nomenclature of glycosaminoglycans
and proteoglycans. Glycoconjugate Journal, 1993. 10: p. 419-421.
103. Sarrazin, S., W.C. Lamanna, and J.D. Esko, Heparan sulfate proteoglycans. Cold Spring Harbor perspectives in biology, 2011. 3(7): p. a004952.
104. Mikami, T. and H. Kitagawa, Biosynthesis and function of chondroitin sulfate. Biochimica et Biophysica Acta (BBA)-General Subjects, 2013. 1830(10): p. 4719- 4733.
105. Iozzo, R.V., Matrix proteoglycans: from molecular design to cellular function. Annual review of biochemistry, 1998. 67(1): p. 609-652.
32 106. Iozzo, R.V., et al., The biology of perlecan: the multifaceted heparan sulphate
proteoglycan of basement membranes and pericellular matrices. Biochemical Journal, 1994. 302(Pt 3): p. 625.
107. Dı́az-Nido, J., F. Wandosell, and J. Avila, Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides, 2002. 23(7): p. 1323-1332. 108. Iannuzzi, C., G. Irace, and I. Sirangelo, The effect of glycosaminoglycans (GAGs) on
amyloid aggregation and toxicity. Molecules, 2015. 20(2): p. 2510-28.
109. Papy-Garcia, D., et al., Glycosaminoglycans, protein aggregation and neurodegeneration. Current Protein and Peptide Science, 2011. 12(3): p. 258-268. 110. Ariga, T., T. Miyatake, and R.K. Yu, Role of proteoglycans and glycosaminoglycans
in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies--a review. J Neurosci Res, 2010. 88(11): p. 2303-15.
111. Gruys, E., A. Ultee, and N. Upragarin, Glycosaminoglycans are part of amyloid fibrils: Ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold. Amyloid, 2006. 13(1): p. 13-19.
112. Snow, A.D. and T.N. Wight, Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiology of aging, 1989. 10(5): p. 481-497. 113. Van Horssen, J., et al., Heparan sulphate proteoglycans in Alzheimer's disease and
amyloid‐related disorders. The Lancet Neurology, 2003. 2(8): p. 482-492.
114. van Horssen, J., et al., Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiology of aging, 2002. 23(4): p. 537-545.
115. Young, I.D., et al., Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Archives of pathology & laboratory medicine, 1992. 116(9): p. 951-954.
116. Snow, A., et al., Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Laboratory investigation; a journal of technical methods and pathology, 1990. 63(5): p. 601-611.
117. Snow, A.D., et al., Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Experimental neurology, 1996. 138(2): p. 305-317.
118. Lindahl, B., et al., Selective loss of cerebral keratan sulfate in Alzheimer's disease. Journal of Biological Chemistry, 1996. 271(29): p. 16991-16994.
119. Snow, A., et al., Differential Binding of Vascular Cell-Derived Proteoglycans (Perlecan, Biglycan, Decorin, and Versican) to the Beta-Amyloid Protein of Alzheimer′ s Disease. Archives of biochemistry and biophysics, 1995. 320(1): p. 84- 95.
120. Snow, A., et al., Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. Journal of Histochemistry & Cytochemistry, 1992. 40(1): p. 105- 113.
121. Dewitt, D.A., et al., Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Experimental neurology, 1993. 121(2): p. 149-152.
122. Fraser, P.E., A.A. Darabie, and J. McLaurin, Amyloid-β Interactions with Chondroitin Sulfate-derived Monosaccharides and Disaccharides IMPLICATIONS FOR DRUG DEVELOPMENT. Journal of Biological Chemistry, 2001. 276(9): p. 6412-6419. 123. Fraser, P.E., et al., Effects of Sulfate Ions on Alzheimer β/A4 Peptide Assemblies:
Implications for Amyloid Fibril‐Proteoglycan Interactions. Journal of neurochemistry, 1992. 59(4): p. 1531-1540.
33 124. McLaurin, J. and P.E. Fraser, Effect of amino‐acid substitutions on Alzheimer's
amyloid‐β peptide–glycosaminoglycan interactions. European Journal of Biochemistry, 2000. 267(21): p. 6353-6361.
125. Castillo, G.M., et al., The Sulfate Moieties of Glycosaminoglycans Are Critical for the Enhancement of β‐Amyloid Protein Fibril Formation. Journal of neurochemistry, 1999. 72(4): p. 1681-1687.
126. Calamai, M., et al., Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry, 2006. 45(42): p. 12806-12815. 127. Goedert, M., et al., Assembly of microtubule-associated protein tau into Alzheimer-
like filaments induced by sulphated glycosaminoglycans. 1996.
128. Paudel, H.K. and W. Li, Heparin-induced conformational change in microtubule- associated protein Tau as detected by chemical cross-linking and phosphopeptide mapping. Journal of Biological Chemistry, 1999. 274(12): p. 8029-8038.
129. Suk, J.Y., et al., Heparin accelerates gelsolin amyloidogenesis. Biochemistry, 2006. 45(7): p. 2234-2242.
130. Relini, A., et al., Heparin strongly enhances the formation of β2-microglobulin amyloid fibrils in the presence of type I collagen. Journal of Biological Chemistry, 2008. 283(8): p. 4912-4920.
131. Meng, F., et al., Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes. Biochemistry, 2007.
46(43): p. 12091-12099.
132. Carufel, C.A., et al., New insights into the roles of sulfated glycosaminoglycans in islet amyloid polypeptide amyloidogenesis and cytotoxicity. Peptide Science, 2013.
100(6): p. 645-655.
133. Vieira, T.C., et al., Heparin binding confers prion stability and impairs its aggregation. The FASEB Journal, 2014. 28(6): p. 2667-2676.
134. Motamedi-Shad, N., E. Monsellier, and F. Chiti, Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism. Journal of biochemistry, 2009. 146(6): p. 805-814.
135. Solomon, J.P., et al., Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry, 2011.
50(13): p. 2486-2498.
136. Bourgault, S., et al., Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry, 2011. 50(6): p. 1001-1015.
137. Blancas-Mejia, L.M., et al., Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans. J Biol Chem, 2015. 290(8): p. 4953-65.
138. Malik, A. and S. Ahmad, Sequence and structural features of carbohydrate binding in proteins and assessment of predictability using a neural network. BMC Structural Biology, 2007. 7(1): p. 1.
139. Fromm, J., et al., Pattern and spacing of basic amino acids in heparin binding sites. Archives of Biochemistry and Biophysics, 1997. 343(1): p. 92-100.
140. Hileman, R.E., et al., Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays, 1998. 20(2): p. 156-167. 141. Maji, S.K., et al., Amyloid as a depot for the formulation of long-acting drugs. PLoS
34 142. Anoop, A., et al., Elucidating the Role of Disulfide Bond on Amyloid Formation and
Fibril Reversibility of Somatostatin-14 RELEVANCE TO ITS STORAGE AND SECRETION. Journal of Biological Chemistry, 2014. 289(24): p. 16884-16903.
143. Giannattasio, G. and A. Zanini, Presence of sulfated proteoglycans in prolactin secretory granules isolated from the rat pituitary gland. Biochimica et Biophysica Acta (BBA)-Protein Structure, 1976. 439(2): p. 349-357.
144. ÅBorg, C.H., et al., A Sulphomucopolysaccharide‐Protein Complex in the Adrenergic Vesicle (Granule) Fraction from Nerves and Tissue. Acta Physiologica Scandinavica, 1972. 86(3): p. 427-429.
145. Pycock, C., et al., On the possible involvement of sulphomucopolysaccharides in the storage of catecholamines within the central nervous system. Acta Physiologica Scandinavica, 1975. 95(4): p. 373-382.
146. Carlson, S.S. and R. Kelly, A highly antigenic proteoglycan-like component of cholinergic synaptic vesicles. Journal of Biological Chemistry, 1983. 258(18): p. 11082-11091.
147. Margolis, R., et al., Complex Carbohydrate Composition of Large Dense‐Cored Vesicles from Sympathetic Nerve. Journal of neurochemistry, 1987. 49(6): p. 1839- 1844.
148. Nishizuka, M. and Y. Arai, Glycosaminoglycans in the olfactory epithelium and nerve of chick embryos: an immunocytochemical study. Neuroscience research, 1996. 24(2): p. 165-173.
149. Margolis, R.U. and R.K. Margolis, Isolation of chondroitin sulfate and glycopeptidcs from chromaffin granules of adrenal medulla. Biochemical pharmacology, 1973.
22(17): p. 2195-2197.
150. Reggio, H.A. and G.E. Palade, Sulfated compounds in the zymogen granules of the guinea pig pancreas. The Journal of cell biology, 1978. 77(2): p. 288-314.
151. Lagunoff, D., et al., ISOLATION AND PRELIMINARY CHARACTERIZATION OF RAT MAST CELL GRANULES. Laboratory investigation; a journal of technical methods and pathology, 1964. 13: p. 1331.
152. Saridaki, T., et al., Glycosaminoglycans (GAGs) suppress the toxicity of HypF-N prefibrillar aggregates. Journal of molecular biology, 2012. 421(4): p. 616-630.
153. Singh, P.K., et al., Cytotoxic Helix-Rich Oligomer Formation by Melittin and Pancreatic Polypeptide. PloS one, 2015. 10(3): p. e0120346.
154. Vilasi, S., et al., Heparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitro. PloS one, 2011. 6(7): p. e22076.
155. Madine, J., et al., Heparin promotes the rapid fibrillization of a peptide with low intrinsic amyloidogenicity. Biochemistry, 2013. 52(50): p. 8984-8992.
156. Wang, H., P. Cao, and D.P. Raleigh, Amyloid formation in heterogeneous environments: islet amyloid polypeptide glycosaminoglycan interactions. Journal of molecular biology, 2013. 425(3): p. 492-505.
157. Huttner, W.B., H.H. Gerdes, and P. Rosa, The granin-(chromogranin/secretogranin) family. Trends in biochemical sciences, 1991. 16: p. 27-30.
158. Helle, K.B., The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biological Reviews, 2004. 79(04): p. 769-794.
159. Blaschko, H., et al., Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature, 1967. 215: p. 58-59.
35 160. Rosa, P. and A. Zanini, Characterization of adenohypophysial polypeptides by two-
dimensional gel electrophoresis: II. Sulfated and glycosylated polypeptides. Molecular and cellular endocrinology, 1981. 24(2): p. 181-193.
161. Kirchmair, R., et al., Secretoneurin—a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience, 1993. 53(2): p. 359-365.
162. Kim, T., et al., Chromogranin A, an “on/off” switch controlling dense-core secretory granule biogenesis. Cell, 2001. 106(4): p. 499-509.
163. Kim, T., et al., Chromogranin A deficiency in transgenic mice leads to aberrant chromaffin granule biogenesis. The Journal of neuroscience, 2005. 25(30): p. 6958- 6961.
164. Mahapatra, N.R., et al., Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. The Journal of clinical investigation, 2005. 115(7): p. 1942-1952.
165. Montesinos, M.S., et al., The crucial role of chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. The Journal of